Literature DB >> 21479367

microRNA-145 suppresses lung adenocarcinoma-initiating cell proliferation by targeting OCT4.

Rong Yin1, Shuai Zhang, Yaqin Wu, Xiaohu Fan, Feng Jiang, Zhi Zhang, Dongjie Feng, Xirong Guo, Lin Xu.   

Abstract

Recent studies demonstrated that microRNA-145 is downregulated in human cancer cells and may function as a tumor suppressor. However, its role in lung cancer tumorigenesis remains unclear. Here, we demonstrated that upregulation of miR-145 reduced the proliferation and invasion as well as the ratio of CD133-positive initiating cells and the tumorosphere growth capacity of the human lung adenocarcinoma A549 cell line. The direct targeting of miR-145 to OCT4 mRNA was predicted by bioinformatic analysis and validated by a luciferase reporter system. We, therefore, confirmed that miR-145 can impair the proliferation of human lung adenocarcinoma-initiating cells by targeting OCT4 and leads to inhibition of lung cancer development.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21479367     DOI: 10.3892/or.2011.1252

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  33 in total

1.  CCAT2 is a lung adenocarcinoma-specific long non-coding RNA and promotes invasion of non-small cell lung cancer.

Authors:  Mantang Qiu; Youtao Xu; Xin Yang; Jie Wang; Jingwen Hu; Lin Xu; Rong Yin
Journal:  Tumour Biol       Date:  2014-02-07

Review 2.  EGFR-TKI resistance in NSCLC patients: mechanisms and strategies.

Authors:  Yuxin Lin; Xian Wang; Hongchuan Jin
Journal:  Am J Cancer Res       Date:  2014-09-06       Impact factor: 6.166

Review 3.  MicroRNAs in lung cancer.

Authors:  Pooja Joshi; Justin Middleton; Young-Jun Jeon; Michela Garofalo
Journal:  World J Methodol       Date:  2014-06-26

4.  MiR-145 regulates cancer stem-like properties and epithelial-to-mesenchymal transition in lung adenocarcinoma-initiating cells.

Authors:  Jingwen Hu; Mantang Qiu; Feng Jiang; Shuai Zhang; Xin Yang; Jie Wang; Lin Xu; Rong Yin
Journal:  Tumour Biol       Date:  2014-06-06

Review 5.  MicroRNAs and lung cancers: from pathogenesis to clinical implications.

Authors:  Ji Qi; David Mu
Journal:  Front Med       Date:  2012-04-18       Impact factor: 4.592

6.  Treatment with the cancer drugs decitabine and doxorubicin induces human skin keratinocytes to express Oct4 and the OCT4 regulator mir-145.

Authors:  Sathivel Chinnathambi; Susan Wiechert; Ann Tomanek-Chalkley; Michael C Winter; Jackie R Bickenbach
Journal:  J Dermatol       Date:  2012-04-09       Impact factor: 4.005

7.  MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patients.

Authors:  Kai Doberstein; Nico Steinmeyer; Ann-Kathrin Hartmetz; Wolfgang Eberhardt; Michel Mittelbronn; Patrick N Harter; Eva Juengel; Roman Blaheta; Josef Pfeilschifter; Paul Gutwein
Journal:  Neoplasia       Date:  2013-02       Impact factor: 5.715

Review 8.  Sweating the small stuff: microRNAs and genetic changes define pancreatic cancer.

Authors:  Siuwah Tang; Jillian Bonaroti; Sebnem Unlu; Xiaoyan Liang; Daolin Tang; Herbert J Zeh; Michael T Lotze
Journal:  Pancreas       Date:  2013-07       Impact factor: 3.327

Review 9.  The roles of microRNAs and protein components of the microRNA pathway in lung development and diseases.

Authors:  Leah Cushing; Zhihua Jiang; Pingping Kuang; Jining Lü
Journal:  Am J Respir Cell Mol Biol       Date:  2015-04       Impact factor: 6.914

10.  MicroRNA-145 restores contractile vascular smooth muscle phenotype and coronary collateral growth in the metabolic syndrome.

Authors:  Rebecca Hutcheson; Russell Terry; Jennifer Chaplin; Erika Smith; Alla Musiyenko; James C Russell; Thomas Lincoln; Petra Rocic
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-02-07       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.